| Document |
Document Title |
|
JPH0822834B2 |
|
|
JPH0819148B1 |
Anthra(1,2-b)pyran antibiotics of formula (I) are new. R is (II) (antibiotic DC-92B) or (III) (antibiotic DC-92D). Pref. prepn. comprises a culture of a strain of Actinomadura (esp. Actinomadura sp. DO-92, FERM-P 1019). Pref. the antibio...
|
|
JPH0827176A |
PURPOSE: To obtain a sialyl phospholipid used as a liposome resource useful for a drug delivery system in high yield by reacting a halogenated sialic acid tetraacetyl derivative ester with a phosphatidyl alkanol and removing a protecting...
|
|
JPH07116206B2 |
|
|
JPH07116209B2 |
This invention provides a novel compound expressed by the following formula (l): [wherein R<1> denotes a hydrogen atom or CH3CO-, R<2> denotes -COOR<4> (R<4> denotes Na or a methyl group) or (R<5> denotes a hydrogen atom, -COC6H5 or -Si(...
|
|
JPH07110870B2 |
|
|
JPH07304786A |
PURPOSE: To obtain the agent capable of quickly and accurately observing by ESR method the in vivo dynamic behavior of a saccharide compound such as D-glucuronic acid, having 2,2,6,6-tetramethylpiperidinyloxy group as spin labeling segme...
|
|
JPH07304783A |
PURPOSE: To obtain a novel phosphinate ester that is useful as a starting material for producing an antiviral agent and can eliminate the protecting group under mild basic conditions by reacting phosphinic acid with an alcohol or a chlor...
|
|
JPH07107075B2 |
|
|
JPH07107074B2 |
|
|
JPH07103138B2 |
|
|
JPH07103139B2 |
|
|
JPH07103009B2 |
Novel esterified oligosaccharides including at least one esterified disaccharide unit consisting of a uronic acid residue and a hexosamine residue can be topically applied to mammalian skin to improve the appearance of hair and other ben...
|
|
JPH07258093A |
PURPOSE: To provide an agent similar to nerve growth factor, containing a sialyl lactose as an active component, effective for promoting the survival of neurocyte and the maintenance of the function, preventing or ameliorating the aging ...
|
|
JPH0778072B2 |
Sucrosetricarboxylic acid can be prepared by oxidising sucrose with oxygen, where appropriate mixed with inert gases, using a catalyst which is more efficient than platinum/alumina. The product can be employed in detergents or as food ad...
|
|
JPH07206772A |
PURPOSE: To efficiently obtain a 2-keto-L-gulonic acid ester useful for a synthetic intermediate of ascorbic acid in a good yield by esterifying 2-keto-L-gulonic acid with methanol or the like continuously under a specific condition. CON...
|
|
JPH07188285A |
PURPOSE: To provide a novel D-glucopyranuronic acid (derivative) for controlling metabolism, immunity protection, digestion, respiration, pain or the like. CONSTITUTION: This compound is represented by formula I (wherein R1 is Oh, OCH3, ...
|
|
JPH07506344A |
PCT No. PCT/EP93/00327 Sec. 371 Date Oct. 24, 1994 Sec. 102(e) Date Oct. 24, 1994 PCT Filed Feb. 11, 1993 PCT Pub. No. WO93/16087 PCT Pub. Date Aug. 19, 1993Novel Amadori reaction compounds have the formula R1-NH-R2, wherein R1 comprises...
|
|
JPH0737474B2 |
|
|
JPH0789978A |
PURPOSE: To provide 2-keto-3-deoxy-D-glycero-D-galacto-nonoic acid (KDN) powder having low hygroscopicity and high stability. CONSTITUTION: This KDN powder has a melting point of 154-162°C (decomposition), exhibits distinct peak at 160Â...
|
|
JPH0741477A |
PURPOSE: To provide a novel compound useful as the feeding stuff of animals, particularly piglets and cattle and showing the effect of promoting the growth of animals. CONSTITUTION: This compund is an elfamycin derivative represented by ...
|
|
JPH0710875B2 |
Lactose containing physiologically-active sialic acids can be obtained by isolating and recovering the sialic acids together with lactose from a permeate or deproteinization solution obtained by ultrafiltration or heat treatment of whey ...
|
|
JPH06104676B2 |
A process for producing 1-fluoro-glycuronic acids which may contain protected amino groups and their salts, in which glycopyranosylfluorides of mono or oligo-saccharides with at least one primary OH function are oxidised in aqueous solut...
|
|
JPH06345791A |
PURPOSE: To obtain a new compound useful for the treatment or the like of diseases controlled by proteins, influenza, herpes, HIV or the like. CONSTITUTION: The compound of formula I [R1 is H, 1-20C alkyl, 2-20C alkenyl, formula II (R10 ...
|
|
JPH06102672B2 |
|
|
JPH0699417B2 |
|
|
JPH06510745A |
The present invention is drawn to methods for the synthesis of Lewisa derivatives modified at the C-2 and/or C-6 position of GlcNAc employing chemo-enzymatic synthesis. The derivatives find use in the treatment and prevention of diseases.
|
|
JPH0680069B2 |
|
|
JPH06271469A |
PURPOSE: To provide an antiulcer agent containing oligogalacturonic acid as the active component, exhibiting a high activity, excellent in safety and useful for improvement of various kinds of ulcers. CONSTITUTION: The objective antiulce...
|
|
JPH06508114A |
Palytoxin and its naturally-occurring analogs are provided as derivatised prodrugs cleavable with a biological catalyst. These prodrugs are useful in protocols wherein the catalyst can be targeted to cells or tissues which are to be impa...
|
|
JPH06507169A |
The present invention discloses trifluorofucoses and methods of making the same. Also disclosed are trifluorofucose analogs of fucose-containing oligosaccharides, and conjugates of trifluorofucose. Compositions are prepared which combine...
|
|
JPH06211762A |
PURPOSE: To provide the subject new compound having low toxicity, exhibiting strong proliferation suppressing effect on cancer cell and useful as a carcinostatic agent. CONSTITUTION: The compound of formula I (R is residue obtained by re...
|
|
JPH06206892A |
PURPOSE: To provide the new anti-inflammatory agents comprising specific oligosaccharides, capable of forming hydrogen bonds with selectin and are ligands of human selectin receptors and effective in treating inflammatory conditions when...
|
|
JPH0651715B2 |
Described are sialosylcerebrosides having the formula
|
|
JPH06184183A |
PURPOSE: To obtain the subject compound which is a raw material for a sialic acid-containing saccharide chain compound useful for efficiently synthesizing a ganglioside by carrying out a new method for treating a nest of a swallow with h...
|
|
JPH0649714B2 |
A process for preparing a 7-halodeoxylincomycin or an analogue thereof, which comprises reacting lincomycin or an analogue thereof with a thionyl halide and dimethylformamide, under mild conditions.
|
|
JPH0643436B1 |
Trehalostatin is a new substance with the following properties: soluble in water, sparingly soluble in hexane, ether, benzene or petroleum ether. No UV absorption maximum above 220nm. Positive Rydon-Smith colour reaction. Negative Elson-...
|
|
JPH0637500B2 |
The Michael addition products of selected unsaturated aldehydes and ketones with ascorbic acid are useful for stimulating the immune response in animals.
|
|
JPH06135980A |
PURPOSE: To provide a new compound useful as a metastasis inhibitor or carcinostatic. CONSTITUTION: The objective compound (salt) of the formula having the following physicochemical characteristics: (1) appearance: amphoteric water-solub...
|
|
JPH06135981A |
PURPOSE: To provide a new derivative useful as an intermediate for gangliosides such as GD3, GT1a. or GQ1b. CONSTITUTION: The objective derivative of formula I [R, Rx and R1 are each H or protecting group; n is 1 or 2; A is (2→3) or (2...
|
|
JPH0631286B2 |
|
|
JPH0631291B2 |
|
|
JPH06502857A |
Identification of the sialyl Lewis X determinant as the determinant responsible for ELAM-1-dependent adhesion of neutrophils to endothelium has resulted in the development of a number of agents for binding to ELAM-1 and methods for treat...
|
|
JPH0686684A |
PURPOSE: To provide a method for mass-synthesizing an α2,3-sialylated conjugate by allowing a trans-sialidase to act under a specific condition. CONSTITUTION: A trans-sialidase is allowed to react with SAα2-R1 (R1 and R2 are each indep...
|
|
JPH06501498A |
Galacturonic acid derivatives of formula: R1 being a linear or branched alkyl having 2 to 22 carbon atoms, R being CH-CH(OH)-CO2R2 or -CH(OH)-CH-CO2R2, R2 being hydrogen, R1, an alkali metal atom, an alkaline-earth metal atom, a quaterna...
|
|
JPH0610134B2 |
An amphotericin B composition containing particles of amphotericin B and cholesterol sulfate, in a molar ratio of between about 1:1 to 1:4. The particles, when stored in lyophilized form and reconstituted in an aqueous suspension, have p...
|
|
JPH0588719B2 |
An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 53676. This novel antibiotic is useful as an anticoccidial in chicken...
|
|
JPH0587517B2 |
NEW MATERIAL:A compound expressed by formula I {A is expressed by formulas II-VI or -NHR<1> [R<1> is H, cyclohexyl, (substituted) phenyl, etc.], etc.}. EXAMPLE:The compound expressed by formula VII. USE:An antimicrobial agent and antimyc...
|
|
JPH0586927B2 |
An anti-HTLV-I agent comprising as an effective component a streptovaricin C derivative represented by the general formula (I): wherein R<1> represents an alkyl group having 3 to 7 carbon atoms. The streptovaricin C derivative has good H...
|
|
JPH05320046A |
PURPOSE: To provide a new antitussive having no side effects, containing, as active ingredient, a specific compound such as L-phenylalanine or a pharmaceuti cally permissible salt thereof. CONSTITUTION: This antitussive containing, as ac...
|
